Author: Ken Dropiewski

VenoStent Embarks on Clinical Trial to Improve Success Rate of Vascular Surgery Outcomes

Successful enrollment in initial feasibility trial to support future regulatory submissions and provide better outcomes for patients with end-stage renal disease HOUSTON–(BUSINESS WIRE)–VenoStent, Inc., a clinical-stage tissue engineering company developing tunable, bioabsorbable, smart polymer wraps to fundamentally transform the efficacy of the five million vascular surgeries performed each year, announces […]

Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent

Anticipated New Patent Will Provide Intellectual Property Protection Until Late 2039 WARRINGTON, Pa., Oct. 25, 2021 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the United States Patent and Trademark […]

Karolinska Development’s portfolio company AnaCardio strengthens its organization to facilitate clinical trial of the drug candidate AC01 in heart failure

STOCKHOLM SWEDEN – October 25, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company AnaCardio has strengthened its organization in preparation for the initiation of a phase 1b/2a study of its drug candidate AC01 in patients with heart failure. The company’s goal is to develop an […]

ScottCare Signs Distribution Agreement With Ninety One, Expands Partnership

CLEVELAND–(BUSINESS WIRE)–ScottCare Cardiovascular Solutions (www.scottcare.com) announced that it has signed an agreement with Ninety One Holding, Inc. (www.91.life) to become a principal distributor for Ninety One’s cloud software platform for cardiac implanted device monitoring, effectively expanding the partnership between the two firms. Currently, ScottCare’s 24/7 remote cardiac monitoring service, Ambucor, […]

Use of a Novel, Intermittent Pneumatic Compression Device to Promote Perforator Vein Dilation in Patients with Chronic Renal Failure: The pFACT Trial

October 2021 ISSN 2152-4343 Abstract Objective. Arteriovenous fistula (AVF) creation is an important procedure for hemodialysis in chronic renal failure (CRF) patients. Recent advancements in vascular access have resulted in endovascular AVF (endoAVF) creations. EndoAVFs are less invasive and less expensive when placed. The dilation of the perforator vein pre-procedure is crucial […]

ilumivu Announces Acquisition of Cardiogram and Series A Investment Round to Accelerate Personalized Decision Support Solutions for Healthcare

-The acquisition and funding will support commercialization of the company’s personalized decision support solutions to serve millions of seniors and their caregivers via mobile applications, with a special focus on Medicare Advantage ASHEVILLE, N.C., Oct. 21, 2021 /PRNewswire/ — ilumivu, Inc., a pioneer in predictive and personalized healthcare intervention software utilized at university […]

BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia

SAN CARLOS, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA] a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the treatment of the first patient in its Phase III pivotal CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial for patients […]

Longeveron Announces Activation of Two New Clinical Sites in ELPIS II Trial of Lomecel-B for Hypoplastic Left Heart Syndrome (HLHS)

MIAMI, Oct. 20, 2021 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today the activation of two new clinical sites for the currently enrolling ELPIS II Trial, evaluating Lomecel-B injection into the myocardium of […]